What Physician-Led Weight Management Targets FDA-approved GLP-1/GIP medications including semaglutide and tirzepatide when clinically appropriate after evaluation and labs Focus on lowering body fat and visceral fat, not just total body weight Improved blood sugar control and insulin sensitivity (A1C tracking) Support for healthier LDL cholesterol and lipid profiles Blood pressure monitoring as weight and metabolic health improve Reduction of liver fat (hepatic steatosis) as a key metabolic marker Nutrition and muscle-preservation guidance built into every plan Comprehensive metabolic, lipid, and hormone lab panels before and during your protocol Board-certified neurologist supervision throughout your protocol Telemedicine available for Nevada residents for ongoing management FDA-Approved Medication Options Compared Both medications below are FDA-approved and available now after an evaluation
COVID-19 immunopathology: From acute diseases to chronic sequelae
Estrogen-Like Molecules: Phytoestrogens and Xenoestrogens The study of estrogen-like molecules whose structure and effects are similar to those induced by estrogens has acquired increasing relevance in animals and humans (Molina et al., 2018)
We've been using them safely in medicine for decades nicotine replacement, hormone replacement therapy (HRT), some pain medications, motion sickness drugs, certain heart treatments
Anal Bioanal Chem 385:105113 Tsuchiya M, Suematsu M, Suzuki H (1994) In vivo visualization of oxygen radical-dependent photoemission
In fact, the more significant hemodynamic effects of this agents, conveyed by TGF restoration, led to afferent arteriole vasoconstriction as compared to efferent vasodilation observed with RAS-inhibition ( Pre-clinical studies in genetically modified animal model of T2DM (OLETF rats, Otsuka Long Evans Tokushima fatty rats) have shown high PRA (plasmatic renin activity) levels, without any change in aldosterone levels under dapagliflozin chronic treatment, in accordance with the aforementioned observations of an independent intrarenal RAS ( Moreover, in recent years the use of small interfering RNAs (siRNA), selectively targeting AGT, as a novel approach of interfering with the RAS has shown beneficial cardio- and nephroprotective properties
